logo
Sign in

Agenebio, Inc.

Baltimore, MD · Founded 2008 · Biotech · Private

Orally active small-molecule GABA-A α5 positive allosteric modulator (PAM) for mild cognitive impairment due to Alzheimer's disease

New patent ·
Claim this profile

Follows are private to you and power your alerts

Updated · agenebio.com

Sector
Biotech
Headquarters
Baltimore, MD
Founded
2008
Latest Form D
$500K, Jul 2016
Total capital
$12M
Federal grants
$4.1M
4 awards · 2019–2021
Rank in peer group#225 of 514
Private capital raised
$7.9M
9 Form D · last Jul 2016
123 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
14
26 pending · first 2017
Rank in peer group#16 of 514

Capital timeline

2009201120132015201720192021FEDERAL ↑EQUITY ↓Cumulative $12M$1.1M$2.1M$235K$626K4th Form D$450K9th Form D$500K
2009201320172021FEDERAL ↑EQUITY ↓Cumulative $12M$1.1M$2.1M$626K

Latest events

  • Federal grantHealth and Human S · Phase II · Structurally Diverse GABA-A a5 Positive Allosteric Modulators for Treatment of MCI due to AD$626K
  • Federal grantHealth and Human S · Phase II · Structurally Diverse GABA-A a5 Positive Allosteric Modulators for Treatment of MCI due to AD$235K
  • Federal grantHealth and Human S · Phase II · Structurally Diverse GABA-A a5 Positive Allosteric Modulators for Treatment of MCI due to AD$2.1M
  • Federal grantHealth and Human S · Phase II · Structurally Diverse GABA-A α5 Positive Allosteric Modulators for Treatment of MCI due to AD$1.1M
  • Private capital raisedForm D · SEC · 9th filing$500K
  • Private capital raisedForm D · SEC · 8th filing$400K
  • Private capital raisedForm D · SEC · 7th filing$4.1M
  • Private capital raisedForm D · SEC · 6th filing$1M
  • Private capital raisedForm D · SEC · 5th filing$1M
  • Private capital raisedForm D · SEC · 4th filing$450K
  • Private capital raisedForm D · SEC · 3rd filing$110K
  • Private capital raisedForm D · SEC · 2nd filing$300K
  • Private capital raisedForm D · SEC · 1st filing$50K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 514 peers

Line = median

Biotech · Molecule

  • Federal grants#225 · top 44%
  • Granted patents#16 · top 3%
  • Linked publications#41 · top 8%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants
  • SHARON W. ROSENZWEIG-LIPSONResearcherExecutive OfficerLinked by $4.1M in grants as PI
  • Brian F. StemmeDirectorNamed in SEC Form D filings
  • CHARLES W. CLARVITDirectorNamed in SEC Form D filings
  • FLOYD W. BLOOMDirectorNamed in SEC Form D filings
  • GARDINER SMITHExecutive Officer, DirectorNamed in SEC Form D filings
  • GERALD W. MCLAUGHLINExecutive Officer, DirectorNamed in SEC Form D filings
Show all 14 people
  • JAMES BARRETTDirectorNamed in SEC Form D filings
  • Kristin ShermanExecutive OfficerNamed in SEC Form D filings
  • Michela GallagherDirector, Executive OfficerNamed in SEC Form D filings
  • PATRICK W. LEPOREDirectorNamed in SEC Form D filings
  • Robert F. PostlethwaitExecutive Officer, DirectorNamed in SEC Form D filings
  • RONALD NORDMANNDirectorNamed in SEC Form D filings
  • Timothy F. ParshallExecutive OfficerNamed in SEC Form D filings
  • William RingoDirectorNamed in SEC Form D filings

What it has protected

USPTO · 14 granted of 40
Show all 40 patent records

Recent research by its founders

  • The HOPE4MCI study: A randomized double‐blind assessment of AGB101 for the treatment of MCI due to AD202428 cites
  • Positive Allosteric Modulation of GABAA α5 Receptors Improves Memory performance of rats with Conditions of Hippocampal Hyperactivity20240 cites
  • Sustained Vision Recovery by OSK Gene Therapy in a Mouse Model of Glaucoma202328 cites

Related companies, and why

  • Elevian, Inc.Similar federal contract value in Biotech · null in contracts
  • Momentum Superior Holdings, Inc.Similar federal contract value in Biotech · null in contracts
  • Viridian TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • FILAMENTECH. INC.Similar federal contract value in Biotech · null in contracts
  • Magnet BiomedicineSimilar federal contract value in Biotech · null in contracts
  • GENESEARCH, INC.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .